Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Total studies: 9 Total participants: 1757
1 finding from 1 review
no estimate extracted
9 participants
GRADE not reported
Dactolisib (1 RCT; 62 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes dactolisib (1 RCT; 62 participants) compared with placebo (very low certainty).
2 findings from 1 review
Total studies: 10 Total participants: 2113
1 finding from 1 review
no estimate extracted
10 participants
GRADE not reported
Everolimus
Estimates of effects, ranking, and certainty of evidence for… probably leads to lower everolimus (3 RCT; 632 participants) compared with placebo (moderate certainty).
4 findings from 1 review
HR 0.36 [0.28, 0.46]
3 studies · 632 participants
Moderate
OR 3.29 [2.21, 4.9]
3 studies · 632 participants
Moderate
OR 2.53 [0.95, 6.79]
1 study · 302 participants
Very low
Show 1 more finding
Interferon + SSA (2 RCTs; 171 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon + SSA (2 RCTs; 468 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.34 [0.14, 0.8]
2 studies · 468 participants
Very low
OR 5.71 [1.9, 17.2]
4 studies · 283 participants
Very low
HR 0.23 [0.06, 0.93]
3 studies · 512 participants
Very low
Show 1 more finding
Everolimus + SSA (1 RCT; 39 participants)
Estimates of effects, ranking, and certainty of evidence for… may leads to lower everolimus + SSA (3 RCTs; 739 participants) compared with placebo (low certainty).
4 findings from 1 review
HR 0.38 [0.26, 0.57]
3 studies · 739 participants
Low
OR 15.1 [2.55, 88.9]
1 study · 39 participants
Very low
OR 2.89 [1.61, 5.19]
2 studies · 589 participants
Moderate
Show 1 more finding
Bevacizumab + SSA (1 RCT; 402 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes bevacizumab + SSA (1 RCT; 402 participants) compared with placebo (very low certainty).
3 findings from 1 review
HR 0.36 [0.15, 0.89]
1 study · 402 participants
Very low
OR 45 [3.32, 609]
1 study · 44 participants
Very low
HR 0.18 [0.04, 0.94]
2 studies · 446 participants
Very low
Interferon (1 RCT; 66 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon (1 RCT; 66 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.41 [0.18, 0.94]
1 study · 66 participants
Very low
OR 4.03 [0.86, 18.8]
2 studies · 86 participants
Very low
HR 0.27 [0.07, 1.1]
1 study · 66 participants
Very low
Show 1 more finding
Sunitinib (1 RCT; 171 participants)
Estimates of effects, ranking, and certainty of evidence for… probably leads to lower sunitinib (1 RCT; 171 participants) compared with placebo (moderate certainty).
2 findings from 1 review
Everolimus + bevacizumab + SSA (1 RCT; 150 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes everolimus + bevacizumab + SSA (1 RCT; 150 participants) compared with placebo (very low certainty).
1 finding from 1 review
Surufatinib (1 RCT; 172 participants)
Estimates of effects, ranking, and certainty of evidence for… leads to lower surufatinib (1 RCT; 172 participants) compared with placebo (high certainty).
2 findings from 1 review
SSA (3 RCTs; 586 participants)
Estimates of effects, ranking, and certainty of evidence for… probably leads to lower SSA (3 RCTs; 586 participants) compared with placebo (moderate certainty).
4 findings from 1 review
HR 0.51 [0.34, 0.77]
3 studies · 586 participants
Moderate
OR 2.93 [1.36, 6.32]
7 studies · 796 participants
Moderate
HR 0.34 [0.16, 0.76]
5 studies · 492 participants
High
Show 1 more finding
Total studies: 11 Total participants: 1338
1 finding from 1 review
no estimate extracted
11 participants
GRADE not reported
177‐Lu‐DOTATATE + SSA (1 RCT; 229 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes 177‐Lu‐DOTATATE + SSA (1 RCT; 229 participants) compared with placebo (very low certainty).
2 findings from 1 review
Surufatinib (1 RCT; 198 participants)
Estimates of effects, ranking, and certainty of evidence for… probably leads to higher surufatinib (1 RCT; 198 participants) compared with placebo (moderate certainty).
2 findings from 1 review